# SLV-324 Treatment of Metastatic Solid Tumors

Source: https://onco.cc/trials/nct07108114/  
OnCo record `nct07108114` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of SLV-324 run by Solve Therapeutics, now recruiting.

## Summary

SLV-324 Treatment of Metastatic Solid Tumors is a phase 1 interventional study registered as NCT07108114 by Solve Therapeutics, with 70 participants planned, started 2025-08-25. Conditions recorded: Metastatic Solid Tumors. Interventions recorded: SLV-324 intravenous (IV infusion).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07108114
- Phase: 1
- Setting: A Phase 1 Dose-Escalation Study of SLV-324 in Subjects With Metastatic Solid Tumors
- Sponsor: Solve Therapeutics
- Enrolled: 70

## Sources

- ClinicalTrials.gov NCT07108114: https://clinicaltrials.gov/study/NCT07108114

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [SLV-324](https://onco.cc/drugs/slv-324/)
- companies: [Solve Therapeutics](https://onco.cc/companies/solve-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07108114.json